Technical Analysis for CCCC - C4 Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 1.83% | |
Stochastic Reached Oversold | Weakness | 1.83% | |
BB Squeeze + Lower Band Touch | Range Contraction | 1.83% | |
Outside Day | Range Expansion | 1.83% | |
Lower Bollinger Band Touch | Weakness | 1.83% | |
Oversold Stochastic | Weakness | 1.83% |
Alert | Time |
---|---|
Possible Inside Day | about 14 hours ago |
60 Minute Opening Range Breakdown | about 17 hours ago |
Gap Up Partially Closed | about 18 hours ago |
Gapped Up (Partial) | about 18 hours ago |
Up 5% | about 18 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/20/2024
C4 Therapeutics, Inc. Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.88 |
52 Week Low | 1.06 |
Average Volume | 1,783,563 |
200-Day Moving Average | 4.83 |
50-Day Moving Average | 7.72 |
20-Day Moving Average | 6.49 |
10-Day Moving Average | 6.44 |
Average True Range | 0.48 |
RSI (14) | 37.89 |
ADX | 22.34 |
+DI | 13.88 |
-DI | 21.78 |
Chandelier Exit (Long, 3 ATRs) | 5.86 |
Chandelier Exit (Short, 3 ATRs) | 7.31 |
Upper Bollinger Bands | 7.07 |
Lower Bollinger Band | 5.91 |
Percent B (%b) | 0.17 |
BandWidth | 17.79 |
MACD Line | -0.36 |
MACD Signal Line | -0.37 |
MACD Histogram | 0.0157 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.55 | ||||
Resistance 3 (R3) | 6.59 | 6.48 | 6.48 | ||
Resistance 2 (R2) | 6.48 | 6.37 | 6.46 | 6.45 | |
Resistance 1 (R1) | 6.30 | 6.30 | 6.24 | 6.26 | 6.43 |
Pivot Point | 6.19 | 6.19 | 6.16 | 6.17 | 6.19 |
Support 1 (S1) | 6.00 | 6.07 | 5.95 | 5.96 | 5.79 |
Support 2 (S2) | 5.89 | 6.00 | 5.87 | 5.77 | |
Support 3 (S3) | 5.71 | 5.89 | 5.74 | ||
Support 4 (S4) | 5.67 |